Category: piperazines

On December 31, 2021, Smith, Stephanie M.; Sabnis, Himalee S.; Lewis, Rebecca Williamson; Effinger, Karen E.; Bergsagel, John; Patterson, Briana; Mertens, Ann; Sakamoto, Kathleen M.; Schapira, Lidia; Castellino, Sharon M. published an article.SDS of cas: 380843-75-4 The title of the article was Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias. And the article contained the following:

Targeted anticancer therapies such as BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for chronic myeloid leukemia (CML) and Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph + ALL). However, little is known about long-term risks of TKIs in children. Exposure-based survivorship guidelines do not include TKIs, thus surveillance practices may be variable. We retrospectively examined surveillance for cardiac and endocrine late effects in children receiving TKIs for Ph + leukemias, diagnosed at < 21 years between 2000 and 2018. Frequency of echocardiogram (ECHO), ECG (ECG), TSH (TSH), dual-energy x-ray absorptiometry (DXA), and bone age testing were abstracted. Descriptive statistics were stratified by leukemia type. 66 Patients (CML n = 44; Ph + ALL n = 22) met inclusion criteria. Among patients with CML, ≥1 evaluation was done: ECHO (50.0%), ECG (48.8%), TSH (43.9%), DXA (2.6%), bone age (7.4%). Among patients with Ph + ALL, ≥1 evaluation was done: ECHO (86.4%), ECG (68.2%), TSH (59.1%), DXA (63.6%), bone age (44.4%). Over a median 6.3 and 5.7 years of observation, resp., 2% of patients with CML and 57% with Ph + ALL attended a survivorship clinic. Despite common exposure to TKIs in survivors of Ph + leukemias, patterns of surveillance for late effects differed in CML and Ph + ALL, with the latter receiving more surveillance likely due to concomitant chemotherapy exposures. Targeted therapies such as TKIs are revolutionizing cancer treatment, but surveillance for late effects and referral to survivorship clinics are variable despite the chronicity of exposure. Evidence based guidelines and longer follow-up are needed. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to tyrosine kinase inhibitor pediatric philadelphia chromosome leukemia, bcr-abl leukemia, cml, late-effects, ph + all, surveillance, tyrosine kinase inhibitors, Placeholder for records without volume info and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Diamandas, Alexander; Razon, Mikhail R.; Ramirez-Arcos, Sandra; Brassinga, Ann Karen C. published an article in 2021, the title of the article was The virulence of S. marcescens strains isolated from contaminated blood products is divergent in the C. elegans infection model.Recommanded Product: 86393-32-0 And the article contains the following content:

Bacterial contamination of platelet concentrates (PCs) can occur during blood donation or PC processing, necessitating routine screening to identify contaminated products in efforts to prevent adverse transfusion reactions in recipient patients. Serratia marcescens is a common bacterial contaminant, and its resilient nature coupled with genetic promiscuity imbue this environmental bacterium with resistance to disinfectants and antibiotics enhancing bacterial virulence. In this study, we aim to understand adaptive survival mechanisms through genetic characterization of two S. marcescens strains, CBS11 and CBS12, isolated from PCs by Canadian Blood Services. Genomic analyses of the two strains indicated that CBS11 has one chromosome and one plasmid (pAM01), whereas CBS12 has no plasmids. Phylogenetic analyses show that CBS11 and CBS12 are non-clonal strains, with CBS11 clustering closely with clin. strain CAV1492 and less so with environmental strain PWN146, and CBS12 clustering with a clin. strain AR_0027. Interestingly, pAM01 was most closely related to PWN146p1, a plasmid found in S. marcescens PWN146 strain associated with pinewood nematode Bursaphelenchus xylophilus. Lastly, the genomic diversity of CBS11 and CBS12 was not reflected in the antibiotic resistance profiles as they were remarkably similar to one another, but was reflected in the virulence phenotypes assessed in the Caenorhabditis elegans nematode infection model, with CBS11 being more virulent then CBS12. Taken together, we suggest that S. marcescens environmental isolates that feature evolutionary diverse genomics are better equipped to adapt and thrive in varied environments, such as that of PCs, and therefore is as much of a concern as multi-drug resistance for human infection potential. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 86393-32-0

The Article related to serratia marcescens contaminated blood caenorhabditis elegans infection, c. elegans, genomic analyses, platelet concentrates, serratia macrescens, virulence, Placeholder for records without volume info and other aspects.Recommanded Product: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 29, 2020, Okano, Hideyuki; Yasuda, Daisuke; Fujimori, Koki; Morimoto, Satoru; Takahashi, Shinichi published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. And the article contained the following:

A review. Induced pluripotent stem cells (iPSCs) are increasingly used in the study of disease mechanisms and the development of effective disease-modifying therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Recently, three candidate anti-ALS drugs-ropinirole (ROPI), retigabine, and bosutinib-have been identified in iPSC-based drug screens and are now being evaluated in clin. trials for safety and effectiveness. We review the preclin. data, clin. research design, and rationale for ROPI as an anti-ALS drug candidate compared with those of the other two drugs. We also discuss the use of iPSCs for understanding and monitoring treatment response as well as for new insights into the development of new drugs and therapeutic interventions for major neurodegenerative diseases. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to ropinirole als drug candidate ipscs review, amyotrophic lateral sclerosis, disease modeling, drug repositioning, induced pluripotent stem cells, ropinirole, Placeholder for records without volume info and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Saussele, Susanne; Kohlbrenner, Katharina; Vogelmann, Tobias; Schubert, Tino published an article in 2022, the title of the article was Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis.COA of Formula: C26H29Cl2N5O3 And the article contains the following content:

Real-world data on usage of 1st-, 2nd-, and 3rd-generation tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) are scarce. This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML. This observational study was based on the InGef research database, an anonymized representative claims dataset in Germany (n = 4 million). An incidence and prevalence patient CML cohort was followed for 5 and 3 years. Analyses regarding incidence, prevalence, and therapy distribution were performed descriptively. 151 Patients were included in the incidence and 636 patients in the prevalence cohort. This resulted in an incidence of 1.8 (95% confidence interval [CI]: 1.34-2.20) and a prevalence of 14.9 (95% CI: 13.70-16.03) per 100,000 inhabitants. For the incidence cohort, data on 1st-line therapy were available for 124 patients and distributed across imatinib (N = 52), nilotinib (N = 44), dasatinib (N = 12), chemotherapies as hydroxycarbamide (N = 11), and ponatinib/bosutinib (N = 5). Twenty-six percent of patients switched TKI therapy at least once in 3 years. In the prevalence cohort, 423 patients (66.5%) had claims on existing or newly emerged cardiovascular diseases (CDs). No significant differences (p = 0.32) between TKIs in patients with CD were found. Every fourth patient switched TKI therapy within the first 3 years after treatment initiation. Switches were more likely when hints of disease progression or intolerability were observable in the database. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3

The Article related to human disease progression chronic myeloid leukemia, chronic myeloid leukemia, chronic myeloid leukemia, claims data analysis, real-world evidence, tki, Placeholder for records without volume info and other aspects.COA of Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Han, Yue; Bai, Can; He, Xi-Meng; Ren, Qing-Ling published an article in , the title of the article was P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells.HPLC of Formula: 1428327-31-4 And the article contains the following content:

Atractylenolide I (Atr-I) was found to sensitize a variety of human cancer cells in previous studies. Purinergic P2X7R plays important role in different cancers. However, whether Atr-I could generate antitumor activity in human cervical cancer cells and P2X7R get involved in this effect remain unclear. In this study, Hela (HPV 18 +) and SiHa (HPV 16 +) cells were treated with different doses of Atr-I. The results indicated that agonist and antagonist of P2X7 receptors, BzATP and JNJ-47965567 (JNJ), could suppress the proliferation of Hela and SiHa cells. Atr-I demonstrated a considerable antitumor effect in both human cervical cancer cells in vitro. Atr-I combined with P2X7R agonist, BzATP, restored Atr-I-induced growth inhibition in Hela cells but not in SiHa cells. However, the combinatorial treatment of P2X7R antagonist JNJ and Atr-I has an additive effect on cell growth inhibition in SiHa cells rather than in Hela cells. It implied that P2X7R would get involved in the anti-human cervical cancer cells effect of Atr-I. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).HPLC of Formula: 1428327-31-4

The Article related to atractylenolide anticancer agent p2x7 receptor cervical cancer, atractylenolide i, hela cells, human cervical cancer cells, p2x7rs, siha cells, Placeholder for records without volume info and other aspects.HPLC of Formula: 1428327-31-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2021, Han, Ling; Ma, Yingbo; Dou, Hao; Fan, Wei published an article.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the article was Dual-functional SFP/PAN based nano drug release system for treatment and nutrients. And the article contained the following:

Nano drug delivery systems can control the ordered release of drugs. To achieve the target of supplying therapeutics and nutrients at the same time, a novel nano drug delivery system with a core-shell structure was prepared by coaxial electrospinning. Polyacrylonitrile (PAN) has been used to produce a drug release scaffold in the shell section, mixed with absorbable silk fibroin peptide (SFP) as a nutrient. Ciprofloxacin (CPFX), a broad-spectrum antibiotic, was used as the core, as well as an antibacterial agent. Owing to its low mol. weight, using a pure SFP thin solution to manufacture nanofibers by electrospinning is still tech. challenging. Thus, different ratios of PAN to SFP were used in the shell electrospinning solution In this research, a novel nano dual-functionality drug delivery system has been successfully prepared In vitro testing demonstrated that nanofibers could supply more nutrients with increasing SFP in shell solutions; however, the ability to maintain controlled release was reduced. It was found that the nanofiber membrane had the best controlled drug release capability for a PAN-to-SFP mass ratio of 95:5. Overall, most ciprofloxacin was released in the first 12 h, while the release of SFP was constant throughout the first 24 h. Our modeling demonstrated that the release of CPFX and SFP is best described using a first-order kinetic model. The developed drug delivery system is designed to release antimicrobial drugs in a controlled manner and provide absorbable nutrients simultaneously. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to silk fibroin peptide polyacrylonitrile nutrient nano drug release system, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 14, 2018, Bittirov, A. M.; Kabardiev, S. Sh.; Begieva, S. A.; Kabardiev, Sh. S.; Bittirov, I. A.; Karpushchenko, K. A.; Bittirova, A. A. published a patent.Computed Properties of 86393-32-0 The title of the patent was Ointment type panpharmacon for complex treatment of animal eye diseases and method of producing thereof. And the patent contained the following:

This invention relates to the field of veterinary medicine and an ointment-type panpharmacon for the complex treatment of cattle thelaziosis, complicated by staphylococci, streptococci, chlamydia, Pseudomonas aeruginosa, Hemophilus spp., comprising ciprofloxacin hydrochloride monohydrate, and is characterized in that it contains micronized fenbendazole having a particle size of 25-50 μ, and as an ointment base – an alloy of petrolatum of “”eye ointments”” type and lanolin anhydrous, and a preservative – Nipasol, the components in the agent being in a certain ratio in mass %, per 100 g of ointment. The invention provides an expansion of the arsenal of means for local treatment of cattle thelaziosis, complicated by staphylococci, streptococci, chlamydia, Pseudomonas aeruginosa, Hemophilus spp. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to ointment eye thelaziosis bacterial infection anthelmintic bactericide, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 3, 2003, Wall, Michael G.; Conroy, Peter J. published a patent.Application of 86393-32-0 The title of the patent was Method of treating middle ear infections. And the patent contained the following:

Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to eardrum perforation middle ear infection dexamethasone ciprofloxacin, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 2013, Akbari, Vajihe; Abedi, Daryoush; Pardakhty, Abbas; Sadeghi-Aliabadi, Hojjat published an article.Synthetic Route of 86393-32-0 The title of the article was Ciprofloxacin nano-niosomes for targeting intracellular infections: an in vitro evaluation. And the article contained the following:

In order to propose non-ionic surfactant vesicles (niosomes) for the treatment of intracellular infections, a remote loading method (active drug encapsulation) followed by sonication was used to prepare nano-niosome formulations containing ciprofloxacin (CPFX). Size anal., size distribution and zeta potentials of niosomes were evaluated and then their antimicrobial activity, cellular uptake, cytotoxicity, intracellular distribution, and antibacterial activity against intracellular Staphylococcus aureus infection of murine macrophage-like, J774, cells were investigated in comparison to free drug. Our findings reveal that size and composition of the niosome formula can influence their in vitro biol. properties. Vesicles in the 300-600 nm size range were phagocytosed to a greater degree by macrophages in comparison to other size vesicles. The min. inhibitory concentrations (MICs) of CPFX-loaded niosomes were two to eightfold lower than MICs of free CPFX. In addition, niosome encapsulation of CPFX provided high intracellular antimicrobial activities while free CPFX is ineffective for eradicating intracellular forms of S. aureus. Encapsulation of CPFX in niosomes generally decreased its in vitro cytotoxicity. Our results show that niosomes are suitable drug delivery systems with good efficacy and safety properties to be proposed for drug targeting against intracellular infections. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Synthetic Route of 86393-32-0

The Article related to staphylococcus ciprofloxacin hydrochloride nanoniosome antimicrobial, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 1998, Jorand-Lebrun, Catherine; Valognes, Delphine; Halazy, Serge published an article.COA of Formula: C7H13ClN2O The title of the article was Use of triphosgene for direct preparation of carbamoyl chlorides from tertiary benzylamines. And the article contained the following:

Treatment of tribenzylamine with triphosgene in CH2Cl2 gave dibenzylcarbamoyl chloride in 71% yield. Several other amines, e.g., I (X = CO, MeN), underwent similar reactions. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).COA of Formula: C7H13ClN2O

The Article related to triphosgene reaction tertiary amine, carbamoyl chloride preparation, General Organic Chemistry: Synthetic Methods and other aspects.COA of Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics